The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Cancer is one of the leading causes of human death worldwide. Treatment of cancer
exhausts significant medical resources, and the morbidity and mortality caused by cancer is …

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …

Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that
exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic …

Breast cancer (BC) has different clinical manifestations due to its diverse mechanism of
action that has created many challenges to choosing appropriate treatment. Recent findings …

Recent technological advances in nanoscience and material designing have led to the
development of point-of-care devices for biomolecule sensing and cancer diagnosis. In situ …

Purpose: ARX788 is a novel antibody–drug conjugate (ADC) comprised of an anti-HER2
mAb and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the …

Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …

Simple Summary The progress of next-generation sequencing technologies has raised
huge expectations for precision-medicine therapy approaches in breast cancer and triple …

Breast cancer has an extremely high incidence in women, and its morbidity and mortality
rank first among female tumors. With the increasing development of medicine today, the …